Hepatic tissue engineering for adjunct and temporary liver support

Francois Berthiaume, Arno W. Tilles, Mehmet Toner, Martin Yarmush, Christina Chan

Research output: Chapter in Book/Report/Conference proceedingChapter


Approximately 30,000 patients die each year from end-stage liver disease in the United States. About 80% of these patients have decompensated chronic liver disease, typically caused by alcoholism or chronic hepatitic C infection, and less commonly by a genetic - hepatocellular or anatomic - defect of liver function, or cancer. The other 20% die of acute liver failure (without preexisting chronic liver disease), which has various etiologies, including ischemia-reperfusion injury during liver surgery, acetaminophen poisoning, viral hepatitis, severe sepsis, idiosyncratic drug reactions, etc. Acute liver failure symptoms develop over a period of 6 weeks to 6 months and lead to death in over 80% of the cases, usually from cerebral edema, complications due to coagulopathy, and renal dysfunction. A more severe form of acute liver failure - fulminant hepatic failure - is characterized by a more rapid evolution (2 to 6 weeks).

Original languageEnglish (US)
Title of host publicationTissue Engineering
PublisherCRC Press
Number of pages20
ISBN (Electronic)9781420008333
ISBN (Print)9780849390265
StatePublished - Jan 1 2007
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Engineering(all)
  • Materials Science(all)


Dive into the research topics of 'Hepatic tissue engineering for adjunct and temporary liver support'. Together they form a unique fingerprint.

Cite this